Bioinformatics analysis for the role of CALR in human cancers

Yijun Li¹, Xiaoxu Liu¹, Heyan Chen¹, Peiling Xie¹, Rulan Ma², Jianjun He¹*, Huimin Zhang¹* *

¹ Departments of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China, ² Departments of Surgical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China

* These authors contributed equally to this work.
* chinahjj@163.com (JH); huimin.zhang@xjtu.edu.cn (HZ)

Abstract

Cancer is one of the most important public health problems in the world. The curative effect of traditional surgery, radiotherapy and chemotherapy is limited and has inevitable side effects. As a potential target for tumor therapy, few studies have comprehensively analyzed the role of CALR in cancers. Therefore, by using GeneCards, UALCAN, GEPIA, Kaplan-Meier Plotter, COSMIC, Regulome Explorer, String, GeneMANIA and TIMER databases, we collected and analyzed relevant data to conduct in-depth bioinformatics research on the CALR expression in Pan-cancer to assess the possibility of CALR as a potential therapeutic target and survival biomarker. We studied the CALR expression in normal human tissues and various tumors of different stages, and found that CALR expression was associated with relapse free survival (RFS). We verified the expression of CALR in breast cancer cell lines by vitro experiments. Mutations of CALR were widely present in tumors. CALR interacted with different genes and various proteins. In tumors, a variety of immune cells are closely related to CALR. In conclusion, CALR can be used as a biomarker for predicting prognosis and a potential target for tumor molecular and immunotherapy.

Introduction

Cancer is one of the most important public health problems in the world. According to the Cancer statistics 2021 report [1], there were 19.3 million new cases and 10 million cancer deaths worldwide in 2020. The curative effect of traditional surgery, radiotherapy and chemotherapy is limited and has inevitable side effects. As a new type of therapy, molecular targeted therapy can interfere with specific molecules to prevent the growth, progression and metastasis of tumors. Compared with traditional chemotherapy, molecular targeted therapy has the advantage of being able to deliver drugs with high specificity and low toxicity. Consequently, it is of great significance to find ideal targets and new biomarkers for early diagnosis, improving prognosis and developing molecular targeted therapy for cancers.

Calreticulin (CALR) is a ubiquitous and highly conserved protein in cells. It was initially identified as a protein with the high affinity for calcium ions in the sarcoplasmic reticulum of
CALR in human cancers

Skeletal muscle [2–4]. Recent studies have shown that CALR is involved in the occurrence, proliferation [5, 6], migration and adhesion [7, 8] of the tumor, and mediates cell phagocytosis [9], signal transduction and immune cell death (ICD) [10]. By activating dendritic cells (DC) and cytotoxic T cells, CALR leads to tumor cell ICD [11, 12] as phagocytic signals. It has been reported that compared with normal tissues, the expression level of CALR in colorectal cancer [13] vaginal cancer [14], oral cancer [5], breast ductal carcinoma [15, 16] and PRAD [17] was increased. Moreover, overexpression of CALR has been considered as a reliable biomarker for detecting urothelial carcinoma and predicting the prognosis [18].

As a potential target for tumor therapy, the expression of CALR in most tumors remains unclear and few studies have comprehensively analyzed the role of CALR in cancers. Therefore, according to several large public databases, we conducted in-depth bioinformatics research on the CALR expression in Pan-cancer to assess the possibility of CALR as a potential therapeutic target and survival biomarker, which provided additional information for exploring the mechanism of tumor progression, predicting the prognosis and researching new targeted drugs.

Materials and methods
GeneCards

GeneCards (www.genecards.org) summarizes human gene annotation data comprehensively and authoritatively. Based on genes, it automatically mines and integrates from more than 80 digital sources to form a web-based deep link card that can be used for more than 73,000 human gene entries [19]. In our study, we obtained the CALR mRNA expression information in normal human tissues in GTEx, BioGPS, and SAGE databases according to the GeneCards website.

UALCAN

UALCAN (http://ualcan.path.uab.edu/analysis.html) is an open, interactive network resource that provides data analysis of The Cancer Genome Atlas (TCGA) and MET500 cohort [20]. In our study, we compared the differential expression of CALR in human normal tissues and cancers by UALCAN database analysis. The p-value was generated by the Student’s t-test and p-value < 0.05 was considered statistically significant.

RT-qPCR

Total RNA was extracted, cDNA was obtained using the RNA Fast 200 (Fastagen Biotech; 220010), and converted to cDNA with the PrimeScript™ RT Master Mix (Takara Biotechnology; RR036A). RT-qPCR analysis was performed using PCR primers with the following sequences: CALR, 5’- TGC ACA ACC CAG ATT ACA AGG -3’ and 5’- AAG ATG GTG CCA GAC TTG AC -3’; and 18S rRNA, 5’- GGA CAG GAT TGA CAG ATT GAT AGC -3’ and 5’- TGC CAG AGT CTC GGT CGT TA -3’, with the SYBR Premix Ex Taq™ II (Takara Biotechnology; RR820A) in Bio-Rad CFX96 system (Hercules).

Immunoblot assay. Whole-cell lysates were prepared in RIPA lysis buffer containing a mixture of protease inhibitors. Proteins were separated using SDS-PAGE, blotted onto polyvinylidene difluoride membranes (Millipore), and probed with primary antibodies against CALR (Abcam) and GAPDH (Proteintech) at 4°C overnight. HRP-conjugated secondary antibody (Proteintech) was used. Signals were detected using electrochemiluminescence (Bio-Rad) by the chemiluminescence reagent (Millipore).
GEPIA

GEPIA (http://gepia.cancer-pku.cn/index.html) is an intuitive network application tool from the information of the TCGA and GTEX databases, 9,736 tumors tissues and 8,587 normal samples, and using the standard processing of RNA sequencing data for the output of gene expression analysis [21]. We used GEPIA to explore the expression of CALR in different pathological stages of tumors. \( P < 0.05 \) was considered to be the significant different.

Kaplan-Meier Plotter

The Kaplan-Meier Plotter (http://www.kmplot.com/analysis/) is an online tool for drawing survival curves based on GEO, EGA and TCGA databases [22]. By calculating the 95% confidence interval and P-value, it compared the difference of survival rate between the high-expressed group and low-expressed group. We analyzed the effect of CALR expression on RFS (relapse-free survival) in different cancers by this website.

COSMIC

COSMIC (https://cancer.sanger.ac.uk/cosmic/) is a high-resolution resource for studying the targets and trends of human cancer genetics. Combining the whole genome sequencing results of tumors with individual publications, it showed the information of coding mutations, non-coding mutations, gene fusions, genome rearrangements, abnormal copy number segments, abnormal expression variants and differentially methylated CpG dinucleotides. At present, COSMIC is the most extensive database of cancer mutations in the world [23]. In this study, we used the COSMIC database to analyze the mutation types of CALR in different types of cancers.

Regulome Explorer

Regulome Explorer online tools (http://explorer.cancerregulome.org/) can visually evaluate CALR expression in cancers and its correlation with other genes in the TCGA database. The pairwise correlation of the two genes was calculated by Spearman’s correlation analysis and displayed by the circus diagram. In our study, we only showed genes with p-value > log10.

STRING

STRING (https://string-db.org/) database is an extensive, objective global network which is designed to ingather, integrate and score the published protein-protein interaction (PPI) information, and to supplement this data by scientific calculations and predictions [24]. We built a PPI network associated with CALR by the STRING database.

GeneMANIA

GeneMANIA (http://www.genemania.org) is a user-friendly and flexible website for proposing gene function hypotheses, determining gene priority for the functional analysis, and generating analysis gene list [25]. It can find and predict proteins with similar functions based on a large number of genomics and proteomics data. We explored genes that may interact with CALR according to the GeneMANIA website.

TIMER

TIMER (https://cistrome.shinyapps.io/timer/) is an integrated computing tool which is aimed at researching and visualizing genomics data and tumor immunology [26]. The TIMER
algorithm could explore the relationship between target gene expression in tumor cells and immune infiltration according to the Spearman’s test, and draw the scatter diagram. Spearman’s Rho value and statistical significance are displayed in the upper left corner of the diagram. All p values were two-sided and a p value of <0.05 was considered statistically significant. In this study, TIMER was used for analyzing the relationship between CALR and the immune cell infiltration in different tumors.

In our study, firstly we introduced the molecular characteristics and differential expression of CALR in tumors and normal tissues. The survival analysis was performed between the expression level of CALR and clinical prognosis. The above studies were used to confirm the role of CALR in the occurrence of a variety of tumors. Subsequently, we performed mutation, Genome-wide association and PPI analysis to explore the possible molecular mechanism of CALR carcinogenesis. Finally, we analyzed the relationship between CALR and immune cells in different tumor cells to explore the CALR related tumor immune mechanism and the possibility of CALR as a target of immunotherapy.

The Ethics Committee of the First Affiliated Hospital of Xian Jiaotong University exempted the review of the study because all these databases are publicly available.

Results

CALR mRNA in normal tissues

In order to explore the expression pattern of CALR under physiological conditions, we detected the expression of CALR mRNA in all types of normal tissues, which can provide clues for the function of the gene. The expression of CALR mRNA in human normal tissues was analyzed according to GTEx, BioGPS, and SAGE databases from the GeneCards website. As shown in Fig 1, CALR mRNA was expressed differently in different tissues, with the highest expression in the liver according to the GTEx database and in smooth muscle based on the BioGPS database. While in the SAGE databases, the kidney is the tissue with the highest CALR mRNA expression in the human body.

The expression of CALR in cancers

To investigate the role of CALR in cancers, we detected the CALR expression in 23 types of tumors and corresponding normal tissues using the UALCAN database. As shown in Fig 2A and Table 1, CALR was up-regulated in 16 types of tumors compared with the corresponding normal tissues, which indicated that CALR may play an oncogenic role in most cancer types. However, in thyroid carcinoma (THCA), the expression of CALR decreased and there was no significant change of expression in the other five tumors, which may be related to different carcinogenic mechanisms in different tumors.

Since breast cancer (BC) is the most common malignancy worldwide [1], we further tested the mRNA and protein expression of CALR in immortalized breast epithelial cells (MCF-10A) and six different human BC cell lines, which encompassed the major clinical categories of BC based on expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2): MCF-7 is ER+PR+HER2− (Luminal A molecular subtype); HCC1954 and MDA-MB-453 are ER−PR−HER2+ (HER2-enriched subtype), and MDA-MB-231, BT549 and SUM159 are ER−PR−HER2− (Basal-like subtype) [27]. Reverse transcription (RT) and quantitative real-time PCR (qPCR) and immunoblot (IB) assays revealed that CALR mRNA and protein were more highly expressed in all 6 BC cell lines compared to MCF-10A cells, and highest expression was observed in the Basal-like cell lines (Fig 2B).
Correlation of CALR expression and pathological stages of tumors

In order to determine whether CALR is associated with tumor progression, we further evaluated the relationship between the CALR and tumor pathological stages based on the GEPIA. The expression of CALR increases with tumor progression in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA) and kidney renal clear cell carcinoma (KIRC). While in colon adenocarcinoma (COAD) and THCA, down-regulated CALR is associated with the higher tumor stage (Fig 3). This indicates different correlation between CALR and tumor progression in different tumors. In BLCA, BRCA and KIRC, higher expression of CALR was associated with more advanced tumor which could be used as an indication of rapid tumor progression.

CALR expression and RFS of cancers

To further investigate the relationship between CALR expression and tumor prognosis, we used the Kaplan-Meier Plotter to study the correlation between CALR and relapse-free survival (RFS). According to the results of Kaplan-Meier analysis, higher CALR expression correlated
with worse RFS in KIRC, liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), kidney renal papillary cell carcinoma (KIRP) and sarcoma (SARC). However, in ovarian serous cystadenocarcinoma (OV) and THCA, higher expression of CALR tends to have better RFS (Fig 4). The above data suggests that CALR expression exhibit different effect on patients’ survival among tumors, which indicates a different role played by CALR in the biological characteristics among different tumors.

Fig 2. The differential expression of CALR in human normal tissues and cancers by UALCAN database analysis. Note: P value < 0.05 is considered statistically significant.

https://doi.org/10.1371/journal.pone.0261254.g002
CALR mutations in cancers

The study of gene mutation in tumors can provide a possible direction for etiology research and targeted therapy. Therefore, we performed mutation type analysis in various types of tumors.

Table 1. The expression level of CALR in tumors analysis compared with normal tissue by UALCAN database.

| Tumor type | Higher                                                                 | Lower                                                                 |
|------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
|            | BLCA, BRCA, CESC, CHOL, COAD, ESCA, GBM, HNSC                         | KIRC, LIHC, LUAD, LUSC, PRAD, READ, STAD, UCEC                         |
|            | KICH, KIRP, PAAD, PCPG, SARC, THYM                                     |                                                                        |

Note: P value < 0.05 is considered statistically significant.

https://doi.org/10.1371/journal.pone.0261254.t001

Fig 3. Correlation between CALR expression with pathological stages of tumors (GEPIA). Note: P value < 0.05 is considered statistically significant.

https://doi.org/10.1371/journal.pone.0261254.g003
including nonsense, missense, synonymous and complex mutations, frameshift insertion, inframe and frameshift deletion and others (Fig 5 and Table 2). The missense mutation occurred most frequently and was detected in 17 types of tumors. Among the base-pair mutations, G > T, C > T and G > A mutations were most common, which were observed in 13, 10 and 10 cancer types, respectively (S1 Fig). According to cBioPortal, we detected 34 mutations between 0 and 417 amino acids (S2A Fig). In the TCGA database, ovarian cancer, uterine cancer, uterine carcinosarcoma and mesothelioma had higher mutation levels (S2B Fig). These results suggest that most tumors with high expression of CALR have a high tumor mutation burden.

**Genome-wide association of CALR in cancers**

In order to study the molecular mechanism and function of the CALR gene in tumorigenesis, we conducted the genome-wide association analysis on CALR and drew the circus diagram to display the interaction network between CALR and other genes in different tumors (Fig 6). In the circus diagram, circular layout edges show the relevance, the outer loop shows cytogenetic bands and the inner loop indicates associations with features of lacking genomic coordinates. The connected curve represents a pair of genes with P value < -log10 of the correlation between DNA methylation, somatic copy number, somatic mutation and protein level according to Spearman’s correlation analysis. As shown in Fig 6, a large number of genes are significantly correlated with CALR detected in BRCA, THCA, esophageal carcinoma (ESCA), stomach adenocarcinoma (STAD), KIRC, and glioblastoma multiforme (GBM), indicating that CALR is closely related to the other genes in the genome of these types of cancers. The specific genes associated with CALR in different tumors and their correlations are shown in S1 Table.

**PPI network of CALR**

The PPI network can provide a basis for exploring the biological behavior of CALR in carcinogenesis. According to the analysis of binding protein with CALR screened by String tool, we obtained a total of 21 corresponding proteins supported by experimental evidence (Fig 7A). Subsequently, we studied the interactive network of CALR with other genes through GeneMAnnA database (Fig 7B). Through the cross analysis of the above two databases, we found 5 common members—PDIA3, B2M, GANAB, CANX, TAPBP, which suggests the biological behavior of CALR may be related to the above 5 genes/proteins.

**Immune cell infiltration of CALR in cancers**

Previous studies have shown that CALR can participate in several aspects of tumor immune regulation [10–12, 28]. Thus, we used the Timer database to study the correlation between CALR and 6 kinds of immune cell infiltrations in 39 types of tumors, including B cells, CD8⁺ T cells, CD4⁺ T cells, macrophages, neutrophils and DCs (S3 Fig). According to the Cancer statistics 2020 report [29], the highest incidence rate of cancer for females is breast cancer, lung cancer and colorectal cancer. For males, the 3 most common cancers are prostate, lung and bronchus, and colorectal. Therefore, we list the results of immune cell infiltration in these tumors in Fig 8. Among the five most common human tumors, CALR is correlated with 4 kinds of immune cells in breast cancer and colon cancer (p<0.05). These findings suggest that the carcinogenic mechanism of CALR may be related to anti-tumor immunity, and CALR may have potential to impact the immunotherapy.

**Discussion**

As a multifunctional protein, CALR was previously considered to be a resident protein of the sarcoplasmic reticulum, with the characteristics of Ca²⁺ buffer and molecular chaperone.
scientists found that the conditional medium containing CALR released from cultured cells can kill tumor cells and reduce angiogenesis [30, 31], and some studies suggested that CALR may participate in the clearance of tumor cells by activating the immune system [32, 33], the role of CALR played in tumor progression and anti-tumor immunity gained more and more attention. However, the effect of CALR on tumor prognosis, its relationship with the immune system and the underlying mechanisms in pan-cancer has not been well characterized. Therefore, we applied bioinformatics analysis to verify the possibility of CALR as an emerging and accurate tumor biomarker for targeted therapy.

As shown in Fig 1, the distribution of CALR in normal tissues is different, which may be related to the presence of CALR in the sarcoplasmic reticulum. Therefore, CALR is highly expressed in ER-rich tissues or tissues involved in a large number of protein syntheses, such as the liver, kidney, and thyroid.

CALR is involved in many important aspects of cancer, including cell proliferation, adhesion and migration, phagocytosis, integrin signal transduction, ICD, etc. The increase of CALR level is highly correlated with the occurrence of different types of cancer. For example,
overexpression of CALR has been found in breast cancer [16], bladder cancer [34], PRAD [17], gastric cancer [35], colon cancer [37], pancreatic cancer [38], melanoma [39], esophageal cancer [40] and leukemia [41]. Moreover, the increase of CALR is more likely to cause tumor metastasis, and the mechanism can be explained by that as a major calcium homeostasis regulator, CALR participates in tumor metastasis through regulating Ca^{2+} signal to induce cell migration [42]. Another possible reason is that CALR actively regulates cell migration and cell survival in the anoikis which is caused by the lack of matrix attachment [43]. In addition, higher expression of CALR is also associated with the more
aggressive malignant processes and poorer prognosis in esophageal cancer [37], gastric cancer [7] and breast ductal carcinoma [44], which is also confirmed in our study. In most tumors,
overexpression of CALR was associated with the higher stage and worse prognosis. Notably, the opposite situation existed in individual tumors, which may be caused by different mutation types (Fig 5) and associated genes (Fig 6) of CALR in different cancer types and needs further validation experimentally.

In order to study the molecular mechanism of CALR involved in tumor progression, we used String and GeneMANIA databases finding that PDIA3, B2M, GANAB, CANX, and TAPBP interact with CALR. It has been found that PDIA3 and CALR are highly co-expressed in micrometastasis pancreatic cancer cell lines PC-1 and Capan-2 [45]. DNMT inhibitors can
play an anti-tumor role in colon and ovarian cancer by up-regulating B2M and CALR [46]. GANAB and CANX belong to endoplasmic reticulum protein chaperones, which cooperate with CALR to regulate endoplasmic reticulum stress in osteoarthritis and asthma, respectively [47, 48]. In triple-negative breast cancer patients, down-regulation of CALR and TAPBP tend to indicate a poor prognosis [49]. Previous studies have shown that the carcinogenic mechanism of CALR is related to the exposure of malignant primordial cells to CALR, HSP70 and HSP90 on the plasma membrane [28]. HSP70 and HSP90 are important molecular chaperones to regulate oncoprotein stability and promote tumorigenesis [50]. In our study, HSP90 and CALR were detected to have an interactive relationship. The specific mechanism needs further experimental verification.

CALR plays a key role in anti-tumor immunity. Aging neutrophils and surviving cancer cells are susceptible to be labeled by CALR which is secreted from macrophages, thus releasing the "eat me" signal [51]. Through antigen-presenting cells (APC), DC "sense" immunogenicity and mediate phagocytosis. At the same time, DC provides sufficient co-stimulation to T cells to stimulate the production of tumor-specific CD8+ T cells [52]. It may explain why drugs that trigger CALR exposure can activate the immune system when combined with conventional chemotherapy, thus promoting cancer ICD [11], as reported anthracyclines and other apoptosis promoting drugs were used to treat colon cancer [12]. In our study, using 22 databases, we studied 39 common tumors. The results showed that CALR was associated with the expression of one or more immune cells in 35 tumors. These results demonstrate that CALR has great value as a potential target for immunotherapy.

Inevitably, there are still some limitations in our research. Our research mainly focused on the bioinformatics analysis of CALR expression and potential molecular mechanism in tumors, and we only verified the CALR expression in breast cancer cell lines in vitro. The
results of bioinformatics analysis need further experiments verification and explore the specific mechanism in vivo and in vitro.

**Conclusion**

In conclusion, we comprehensively analyzed CALR from the perspective of public database and cell lines, and summarized the gene expression, clinical prognosis and molecular mechanism of CALR in different tumors. Our research suggests that CALR can be used as a biomarker to predict tumor prognosis and a potential target for tumor molecules and immunotherapy in specific tumors, which has the value for further deepen research.

**Supporting information**

S1 Fig. Pie chart showing the base-pair mutations of CALR in human cancers based on the COSMIC database.  
(TIF)

S2 Fig. (a) Mutation diagram of CALR across protein domains in different cancer types. (b) Mutation level of CALR in the TCGA database.  
(TIF)

S3 Fig. The correlation between CALR and the immune cell infiltration in 39 cancers.  
(TIF)

S1 Checklist.  
(DOCX)

S1 Table. Correlation analysis of related genes and CALR in tumors based on the Regu-lome Explorer.  
(XLSX)

**Author Contributions**

**Conceptualization:** Yijun Li, Jianjun He.

**Data curation:** Yijun Li, Xiaoxu Liu, Heyan Chen, Peiling Xie, Rulan Ma.

**Formal analysis:** Yijun Li, Xiaoxu Liu, Heyan Chen, Peiling Xie.

**Funding acquisition:** Huimin Zhang.

**Investigation:** Yijun Li, Xiaoxu Liu, Rulan Ma.

**Methodology:** Heyan Chen, Peiling Xie, Rulan Ma.

**Project administration:** Rulan Ma.

**Resources:** Yijun Li, Heyan Chen.

**Supervision:** Peiling Xie, Rulan Ma, Jianjun He, Huimin Zhang.

**Validation:** Yijun Li, Xiaoxu Liu, Heyan Chen, Peiling Xie, Jianjun He, Huimin Zhang.

**Visualization:** Heyan Chen.

**Writing – original draft:** Yijun Li, Huimin Zhang.

**Writing – review & editing:** Jianjun He, Huimin Zhang.
References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209–249. https://doi.org/10.3322/caac.21660 PMID: 33538338

2. Michalak M, Campbell KP, MacLennan DH. Localization of the high affinity calcium binding protein and an intrinsic glycoprotein in sarcoplasmic reticulum membranes. J Biol Chem. 1980; 255(4):1317–26 PMID: 6766447

3. Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M. Calreticulin: one protein, one gene, many functions. Biochem J. 1999; 344 Pt 2:281–92 PMID: 10567207

4. Ostwald TJ, MacLennan DH. Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J Biol Chem. 1974; 249(4):1317–26 PMID: 4272851

5. Chiang WF, Hwang TZ, Hour TC, Wang LH, Chiu CC, Chen HR, et al. Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. Oral Oncol. 2013; 49(6):534–41. https://doi.org/10.1016/j.oraloncology.2013.01.003 PMID: 23375893

6. Sheng W, Chen C, Dong M, Zhou J, Liu Q, Dong Q, et al. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. J Cell Physiol. 2014; 229(7):2677–87. https://doi.org/10.1002/jcp.24519 PMID: 24264800

7. Cheng CN, Chang CC, Su TE, Hsu WM, Jeng YM, Ho MC, et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol. 2009; 16(2):524–33. https://doi.org/10.1245/s10434-008-0243-1 PMID: 19050968

8. Du XL, Hu H, Lin DC, Xia SH, Shen XM, Zhang Y, et al. Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl). 2007; 85(6):863–75. https://doi.org/10.1007/s00109-007-0159-4

9. Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol. 2007; 25(2):192–3. https://doi.org/10.1038/nbt0207-192 PMID: 17287754

10. Ihara Y, Inai Y, Ikezaki M. Alteration of integrin-dependent adhesion and signaling in EMT-like MDCK cells established through overexpression of calreticulin. J Cell Biochem. 2011; 112(9):2518–28. https://doi.org/10.1002/jcb.23176 PMID: 17804698

11. Obeid M, Panaretakis T, Tesniere A, Joza N, Apeoto L, Apetoh L, et al. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res. 2007; 67(17):7941–4. https://doi.org/10.1158/0008-5472.CAN-07-1622 PMID: 17804698

12. Obeid M, Tesniere A, Panaretakis T, Tufo R, Joza N, van Endert P, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev. 2007; 220:22–34. https://doi.org/10.1111/j.1600-065X.2007.00567.x PMID: 17979837

13. Alfonso P, Nunez A, Madrazo-Gurpide J, Lombardia L, Sanchez L, Casal J. Proteomic expression analysis of colorectal cancer by two-dimension differential gel electrophoresis. Proteomics. 2005; 5(10):2602–11. https://doi.org/10.1002/pmic.200401196 PMID: 15924290

14. Hellman K, Alaiya AA, Schedvin S, Steinberg W, Hellstrom AC, Auer G. Protein expression patterns in primary carcinoma of the vagina. Br J Cancer. 2004; 91(2):319–26. https://doi.org/10.1038/sj.bjc.6601944 PMID: 15193839

15. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis. 1997; 18(15):2832–41. https://doi.org/10.1002/elps.1150181519 PMID: 9504817

16. Chahed K, Kabbage M, Ehret-Sabatier L, Lemaitre-Guillier C, Remadi S, Hoebeke J, et al. Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF mass spectrometry analyses. Int J Oncol. 2005; 27(5):1425–31 PMID: 16211239

17. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, et al. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol. 2000; 21(1):1–9. https://doi.org/10.1155/2000/351963 PMID: 1150181519 PMID: 1150181519

18. Kageyama S, Isono T, Matsuda S, Ushio Y, Satomura S, Terai A, et al. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int J Urol. 2009; 16(5):481–6. https://doi.org/10.1111/j.1442-2042.2009.02287.x PMID: 19389084

19. Paolacci S, Precone V, Acquaviva F, Chiurazzi P, Fulcheri E, Pinelli M, et al. Genetics of lipedema: new perspectives on genetic research and molecular diagnoses. Eur Rev Med Pharmacol Sci. 2019; 23(13):5581–94. https://doi.org/10.26355/eurrev_201907_18292 PMID: 31298310
20. Chandrashekar DS, Bashel B, Balasubramanyan SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649–58. https://doi.org/10.1016/j.neo.2017.05.002 PMID: 28732212

21. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98–W102. https://doi.org/10.1093/nar/gkx247 PMID: 28407145

22. Nagy A, Lanczky A, Menyhart O, Györfy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018; 8(1):9227. https://doi.org/10.1038/s41598-018-27521-y PMID: 29907753

23. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015; 43(Database issue):D805–11. https://doi.org/10.1093/nar/gku1075 PMID: 25355519

24. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47(D1):D607–D13. https://doi.org/10.1093/nar/gky1131 PMID: 30476243

25. Warda-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010; 38(Web Server issue):W214–20. https://doi.org/10.1093/nar/gkq537 PMID: 20576703

26. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108–e10. https://doi.org/10.1158/0008-5472.CAN-17-0307 PMID: 29092952

27. Dai X, Cheng H, Bai Z, Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J Cancer. 2017; 8(16):3131–41. https://doi.org/10.7150/jca.18457 PMID: 29158785

28. Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, et al. Calreticulin exposure by malignant blast correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood. 2016; 128(26):3113–24. https://doi.org/10.1182/blood-2016-08-731737 PMID: 27802968

29. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7–30. https://doi.org/10.3322/caac.21590 PMID: 31912902

30. Dai E, Stewart M, Ritchie B, Mesael N, Raha S, Kolodziejczyk D, et al. Calreticulin, a potential vascular regulatory protein, reduces intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 1997; 17(11):2359–68. https://doi.org/10.1161/01.atv.17.11.2359 PMID: 9409020

31. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med. 1998; 188(12):2349–56. https://doi.org/10.1084/jem.188.12.2349 PMID: 9858521

32. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007; 81(1):1–5. https://doi.org/10.1111/j.1749-6632.2010.05740.x PMID: 20958319

33. Martins I, Kepp O, Galluzzi L, Senvoliva L, Schlemmer F, Adjemian S, et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci. 2010; 1209:77–82. https://doi.org/10.1111/j.1749-6632.2010.05740.x PMID: 20958319

34. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004; 50(5):857–66. https://doi.org/10.1373/clinchem.2003.027425 PMID: 14764641

35. Chen CN, Lin JJ, Lee H, Cheng YM, Chang KJ, Hsieh FJ, et al. Association between color doppler vascular index, angiogenesis-related molecules, and clinical outcomes in gastric cancer. J Surg Oncol. 2009; 99(7):402–8. https://doi.org/10.1002/jso.21193 PMID: 19418489

36. Kim YM, Kim HJ, Song EJ, Lee KJ. Glucuronic acid is a novel inducer of heat shock response. Mol Cell Biochem. 2004; 259(1–2):23–33. https://doi.org/10.1023/b:mcbi.0000021341.38630.52 PMID: 15124904

37. Vougas K, Gaitanarou E, Marinos E, Kittas C, Voloudakis-Baltatzis IE. Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies. J BUON. 2008; 13(1):101–7 PMID: 18407995

38. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenso JK, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004; 64(15):5504–10. https://doi.org/10.1158/0008-5472.CAN-04-0077 PMID: 15289361

39. White TK, Zhu Q, Tanzer ML. Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem. 1995; 270(27):15926–9. https://doi.org/10.1074/jbc.270.27.15926 PMID: 7608143
40. Nishimori T, Tomonaga T, Matsushita K, Oh-Ishi M, Kodera Y, Maeda T, et al. Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics. 2006; 6(3):1011–8. https://doi.org/10.1002/pmic.200500262 PMID: 16400690

41. Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood. 2005; 106(4):1369–75. https://doi.org/10.1182/blood-2004-11-4392 PMID: 15855281

42. Gold LI, Rahman M, Blechman KM, Greives MR, Churgin S, Michaels J, et al. Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects. J Investig Dermatol Symp Proc. 2006; 11(1):57–65. https://doi.org/10.1038/sj.jidsymp.5650011 PMID: 17069011

43. Papp S, Fadel MP, Kim H, McCulloch CA, Opas M. Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activity. J Biol Chem. 2007; 282(22):16585–98. https://doi.org/10.1074/jbc.M701011200 PMID: 17389592

44. Lwin ZM, Guo C, Salim A, Yip GW, Chew FT, Nan J, et al. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod Pathol. 2010; 23(12):1559–66. https://doi.org/10.1038/modpathol.2010.173 PMID: 20834237

45. Liu X, Weng Y, Liu P, Sui Z, Zhou L, Huang Y, et al. Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics. Onco Targets Ther. 2018; 11:3345–57. https://doi.org/10.2147/OTT.S162470 PMID: 29922073

46. Siebenkas C, Chiappinelli KB, Guzzetta AA, Sharma A, Jeschke J, Vatapalli R, et al. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLoS One. 2017; 12(8):e0179501. https://doi.org/10.1371/journal.pone.0179501 PMID: 28622390

47. de Seny D, Bianchi E, Bawir D, Cobraiville G, Collin C, Deliege M, et al. Proteins involved in the endoplasmic reticulum stress are modulated in synovitis of osteoarthritis, chronic pyrophosphate arthropathy and rheumatoid arthritis, and correlate with the histological inflammatory score. Sci Rep. 2020; 10(1):14159. https://doi.org/10.1038/s41598-020-70803-7 PMID: 32687899

48. Pathinayake PS, Waters DW, Nichol KS, Brown AC, Reid AT, Hsu AC, et al. Endoplasmic reticulum-unfolded protein response signalling is altered in severe eosinophilic and neutrophilic asthma. Thorax. 2021. https://doi.org/10.1136/thoraxjnl-2020-215979 PMID: 34510013

49. Pedersen MH, Hood BL, Beck HC, Conrads TP, Dilzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. Oncoimmunology. 2017; 6(5):e1305531. https://doi.org/10.1080/2162402X.2017.1305531 PMID: 28638726

50. Nilika, Blackman JS, Knighton LE, Takakuwa JE, Calderwood SK, Truman AW. Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance. Sci Rep. 2020; 10(1):13831. https://doi.org/10.1038/s41598-020-70764-x PMID: 32796891

51. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007; 13(1):54–61. https://doi.org/10.1038/nm1523 PMID: 17187072

52. Wang HT, Lee HI, Guo JH, Chen SH, Liao ZK, Huang KW, et al. Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules. Int J Cancer. 2012; 130(12):2892–902. https://doi.org/10.1002/ijc.26339 PMID: 21805477

PLOS ONE | https://doi.org/10.1371/journal.pone.0261254 December 15, 2021 17 / 17